A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and
tolerability of ASG-5ME and identify the maximum tolerated dose in patients with
pathologically confirmed metastatic pancreatic adenocarcinoma, and to evaluate safety and
tolerability in patients with relapsed or refractory gastric adenocarcinoma.